BR112018001275A2 - métodos para tratar transtornos associados à angiogênese e neovascularização - Google Patents

métodos para tratar transtornos associados à angiogênese e neovascularização

Info

Publication number
BR112018001275A2
BR112018001275A2 BR112018001275A BR112018001275A BR112018001275A2 BR 112018001275 A2 BR112018001275 A2 BR 112018001275A2 BR 112018001275 A BR112018001275 A BR 112018001275A BR 112018001275 A BR112018001275 A BR 112018001275A BR 112018001275 A2 BR112018001275 A2 BR 112018001275A2
Authority
BR
Brazil
Prior art keywords
methods
dimer
patient
neovascularization
angiogenesis
Prior art date
Application number
BR112018001275A
Other languages
English (en)
Inventor
Burian Gabriela
Dornbush Kirk
Greene William
Original Assignee
Iconic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iconic Therapeutics Inc filed Critical Iconic Therapeutics Inc
Publication of BR112018001275A2 publication Critical patent/BR112018001275A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

são aqui fornecidos métodos e composições de dímero de imunoconjugado para o tratamento de doenças associadas com angiogênese e neovascularização. em um aspecto, a invenção refere-se a um método para tratar a degeneração macular relacionada à idade úmida (dmri) em um olho de um paciente que dele necessite. o método compreende administrar ao paciente, em sessões de múltiplas dosagens, uma composição compreendendo uma quantidade eficaz de um dímero de imunoconjugado, em que as subunidades de monômero do dímero compreendem, cada uma, proteína do fator viia humana (fviia) mutada conjugada ao domínio fc da imunoglobulina humana g1 (igg1).
BR112018001275A 2015-07-22 2016-07-22 métodos para tratar transtornos associados à angiogênese e neovascularização BR112018001275A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562195709P 2015-07-22 2015-07-22
PCT/US2016/043617 WO2017015582A1 (en) 2015-07-22 2016-07-22 Methods for treating disorders associated with angiogenesis and neovascularization

Publications (1)

Publication Number Publication Date
BR112018001275A2 true BR112018001275A2 (pt) 2018-09-18

Family

ID=57835306

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001275A BR112018001275A2 (pt) 2015-07-22 2016-07-22 métodos para tratar transtornos associados à angiogênese e neovascularização

Country Status (11)

Country Link
US (2) US20180207292A1 (pt)
EP (1) EP3324960A4 (pt)
JP (1) JP2018524391A (pt)
KR (1) KR20180034518A (pt)
CN (1) CN108024994A (pt)
AU (1) AU2016297178A1 (pt)
BR (1) BR112018001275A2 (pt)
CA (1) CA2990837A1 (pt)
MX (1) MX2018000869A (pt)
RU (1) RU2018106348A (pt)
WO (1) WO2017015582A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
BR112018013407A2 (pt) 2015-12-30 2018-12-18 Kodiak Sciences Inc anticorpos e conjugados dos mesmos
EP3442554A4 (en) * 2016-04-14 2019-12-04 Iconic Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATING DISEASES RELATED TO NEOVASCULARIZATION
WO2018140611A1 (en) * 2017-01-25 2018-08-02 Iconic Therapeutics, Inc. Methods for treating disorders associated with angiogenesis and neovascularization
EP3687555A4 (en) * 2017-09-27 2021-07-21 Ohio State Innovation Foundation TISSUE FACTOR TISSUE CAR-NK AND CAR-T-CELL THERAPY
KR102428619B1 (ko) 2019-09-25 2022-08-04 대구가톨릭대학교산학협력단 망막병증 치료용 약물 방출 콘택트렌즈 및 이의 제조방법
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US6924359B1 (en) * 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
AU2003242507A1 (en) * 2002-07-12 2004-02-02 Novo Nordisk A/S A tissue factor binding immunoconjugate comprising factor viia
WO2004064870A2 (en) * 2003-01-22 2004-08-05 Novo Nordisk A/S Radiolabelled tissue factor binding agent and the use thereof
US20080193441A1 (en) * 2003-11-18 2008-08-14 Iconic Therapeutics, Inc. Homogeneous Preparations of Chimeric Protein
US20060052286A1 (en) * 2004-08-13 2006-03-09 Yale University Factor VII conjugates for selectively treating neovascularization disorders
US20070134244A1 (en) * 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis
RS56599B1 (sr) * 2010-06-15 2018-02-28 Genmab As Konjugati humanog antitela sa lekom protiv tkivnog faktora

Also Published As

Publication number Publication date
EP3324960A4 (en) 2019-01-23
WO2017015582A1 (en) 2017-01-26
CN108024994A (zh) 2018-05-11
KR20180034518A (ko) 2018-04-04
US20210236649A1 (en) 2021-08-05
RU2018106348A (ru) 2019-08-22
US20180207292A1 (en) 2018-07-26
AU2016297178A1 (en) 2018-01-25
JP2018524391A (ja) 2018-08-30
MX2018000869A (es) 2018-07-06
EP3324960A1 (en) 2018-05-30
CA2990837A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
BR112018001275A2 (pt) métodos para tratar transtornos associados à angiogênese e neovascularização
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
MX2020005651A (es) Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
BR112018008358A2 (pt) ?composições e métodos para terapia relacionada à microbiota fecal?
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
BR112018014222A2 (pt) método de tratamento da glomerulopatia c3
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
BR112016025312A2 (pt) variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
BR112018074978A2 (pt) anticorpos para alfa-sinucleína e usos dos mesmos
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
BR112016019432A8 (pt) composição terapêutica, kit e seus usos na terapia gênica contra degeneração da retina
BR112018067721A2 (pt) anticorpos específicos para tau hiperfosforilada para o tratamento de doenças oculares
MX2020010968A (es) Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades.
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
EA201100462A1 (ru) Серосвязанные соединения для лечения офтальмологических заболеваний и расстройств
BR112017005235A2 (pt) vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)
PH12021550872A1 (en) Therapeutic compounds
EA201691567A1 (ru) Способы лечения легких травм головного мозга
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
BR112018067554A2 (pt) formulações de testosterona e métodos de tratamento com as mesmas

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]